Literature DB >> 19889940

Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines.

Jan T Poolman1, Carl E Frasch, Helena Käyhty, Pascal Lestrate, Shabir A Madhi, Isabelle Henckaerts.   

Abstract

The history of the pneumococcal polysaccharide enzyme-linked immunosorbent assay (ELISA) is characterized by a continuous search for increased specificity. A third-generation ELISA that uses 22F polysaccharide inhibition has increased the specificity of the assay, particularly at low antibody concentrations. The present work compared various 22F ELISAs and non-22F ELISAs. The comparisons involved three different laboratories, including a WHO reference laboratory, and included sera from subjects from different geographic areas immunized with different pneumococcal conjugate vaccines, including the licensed 7-valent Prevenar vaccine and the 10-valent Synflorix vaccine. All comparisons led to the same conclusion that the threshold defined as 0.35 microg/ml for the WHO non-22F ELISA is lower when any 22F ELISA is used. The use of highly purified polysaccharides for coating further improved the specificity of the assay. In conclusion, we confirm that the 22F ELISA can be recommended as a reference method for the determination of antibodies against pneumococcal polysaccharides.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19889940      PMCID: PMC2812097          DOI: 10.1128/CVI.00289-09

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  28 in total

Review 1.  Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides.

Authors:  Catherine M Wernette; Carl E Frasch; Dace Madore; George Carlone; David Goldblatt; Brian Plikaytis; William Benjamin; Sally A Quataert; Steve Hildreth; Daniel J Sikkema; Helena Käyhty; Ingileif Jonsdottir; Moon H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

2.  Specificities and opsonophagocytic activities of antibodies to pneumococcal capsular polysaccharides in sera of unimmunized young children.

Authors:  Anu Soininen; Maijastiina Karpala; Sirkka-Liisa Wahlman; Hannele Lehtonen; Helena Käyhty
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

3.  A concordance correlation coefficient to evaluate reproducibility.

Authors:  L I Lin
Journal:  Biometrics       Date:  1989-03       Impact factor: 2.571

4.  The reverse cumulative distribution plot: a graphic method for exploratory analysis of antibody data.

Authors:  G F Reed; B D Meade; M C Steinhoff
Journal:  Pediatrics       Date:  1995-09       Impact factor: 7.124

5.  Immunogenic protein contaminants in pneumococcal vaccines.

Authors:  Jigui Yu; David E Briles; Janet A Englund; Susan K Hollingshead; W Paul Glezen; Moon H Nahm
Journal:  J Infect Dis       Date:  2003-03-06       Impact factor: 5.226

6.  Teichoic acid and lipoteichoic acid of Streptococcus pneumoniae possess identical chain structures. A reinvestigation of teichoid acid (C polysaccharide).

Authors:  W Fischer; T Behr; R Hartmann; J Peter-Katalinić; H Egge
Journal:  Eur J Biochem       Date:  1993-08-01

7.  The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

Authors:  E D Shapiro; A T Berg; R Austrian; D Schroeder; V Parcells; A Margolis; R K Adair; J D Clemens
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

Review 8.  The role of complement in the host's defense against Streptococcus pneumoniae.

Authors:  J A Winkelstein
Journal:  Rev Infect Dis       Date:  1981 Mar-Apr

9.  A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection.

Authors:  Keith P Klugman; Shabir A Madhi; Robin E Huebner; Robert Kohberger; Nontombi Mbelle; Nathaniel Pierce
Journal:  N Engl J Med       Date:  2003-10-02       Impact factor: 91.245

10.  Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial.

Authors:  Katherine L O'Brien; Lawrence H Moulton; Raymond Reid; Robert Weatherholtz; Jane Oski; Laura Brown; Gaurav Kumar; Alan Parkinson; Diana Hu; Jill Hackell; Ih Chang; Robert Kohberger; George Siber; Mathuram Santosham
Journal:  Lancet       Date:  2003-08-02       Impact factor: 79.321

View more
  23 in total

1.  A semisynthetic Streptococcus pneumoniae serotype 8 glycoconjugate vaccine.

Authors:  Benjamin Schumann; Heung Sik Hahm; Sharavathi G Parameswarappa; Katrin Reppe; Annette Wahlbrink; Subramanian Govindan; Paulina Kaplonek; Liise-Anne Pirofski; Martin Witzenrath; Chakkumkal Anish; Claney L Pereira; Peter H Seeberger
Journal:  Sci Transl Med       Date:  2017-03-08       Impact factor: 17.956

2.  Serotype-specific anti-pneumococcal IgG and immune competence: critical differences in interpretation criteria when different methods are used.

Authors:  Anne Balloch; Paul V Licciardi; Mimi L K Tang
Journal:  J Clin Immunol       Date:  2012-09-30       Impact factor: 8.317

3.  Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines.

Authors:  Jan Poolman; Carl Frasch; Anu Nurkka; Helena Käyhty; Ralph Biemans; Lode Schuerman
Journal:  Clin Vaccine Immunol       Date:  2010-12-01

4.  Immune Responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination.

Authors:  M A Julie Westerink; Harry W Schroeder; Moon H Nahm
Journal:  Aging Dis       Date:  2011-07-20       Impact factor: 6.745

5.  Safety and Immunogenicity of Pneumococcal Conjugate Vaccine in Preterm Infants: A Meta-Analysis.

Authors:  Kai Duan; Jin Guo; Ping Lei
Journal:  Indian J Pediatr       Date:  2016-11-07       Impact factor: 1.967

6.  Prediction of pneumococcal conjugate vaccine effectiveness against invasive pneumococcal disease using opsonophagocytic activity and antibody concentrations determined by enzyme-linked immunosorbent assay with 22F adsorption.

Authors:  L Schuerman; J Wysocki; J C Tejedor; M Knuf; K-H Kim; J Poolman
Journal:  Clin Vaccine Immunol       Date:  2011-10-12

7.  Randomized, open-label study of the impact of age on booster responses to the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in children in India.

Authors:  Sanjay Lalwani; Sukanta Chatterjee; Jugesh Chhatwal; Anna Simon; Sudheer Ravula; Nancy Francois; Shailesh Mehta; Ana Strezova; Dorota Borys
Journal:  Clin Vaccine Immunol       Date:  2014-07-09

8.  Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial.

Authors:  Alassane Dicko; Olumuyiwa O Odusanya; Abdoulbaki I Diallo; Gaoussou Santara; Amadou Barry; Amagana Dolo; Aminata Diallo; Yetunde A Kuyinu; Omolara A Kehinde; Nancy François; Dorota Borys; Juan P Yarzabal; Marta Moreira; Lode Schuerman
Journal:  BMC Public Health       Date:  2011-11-23       Impact factor: 3.295

9.  Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study.

Authors:  Satoshi Iwata; Naohisa Kawamura; Haruo Kuroki; Yasunobu Tokoeda; Mitsunobu Miyazu; Asayuki Iwai; Tomohiro Oishi; Tomohide Sato; Akari Suyama; Nancy François; Fakrudeen Shafi; Javier Ruiz-Guiñazú; Dorota Borys
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

10.  Impact of Pneumococcal Conjugate Vaccine Administration in Pediatric Older Age Groups in Low and Middle Income Countries: A Systematic Review.

Authors:  Kimberly Bonner; Emily Welch; Kate Elder; Jennifer Cohn
Journal:  PLoS One       Date:  2015-09-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.